trial
as of 2026-07-01Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
NCTId NCT01266174
at a glance
Phase 2 · Completed
Enrollment 31 (actual)
Sponsored by Amarantus BioScience Holdings, Inc.
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
31 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-08
Primary completion
2012-09
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Amarantus BioScience Holdings, Inc.Lead Sponsor
Investigators
1
John G Csernansky, MDPrincipal Investigator
Sites
6 total
Los Angeles, United StatesChicago, United StatesCatonsville, United StatesBoston, United StatesNew York, United StatesDurham, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
31
Phase
PHASE2
Primary Completion Date
2012-09
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person